Skip to main content

Market Overview

BridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing

Share:
  • BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i).
  • LGMD2i is an inherited recessive muscular dystrophy caused by mutation of fukutin-related protein (FKRP), leading to chronic muscle injury and loss, muscle weakness, and disability.
  • BBP-418 is designed to bypass the metabolic defect in LGMD2i by providing the FKRP enzyme with precursor sugar molecules that supplement the body's natural sugars used by FKRP to glycosylate the αDG protein on muscle cells.
  • The 16-subject trial will assess the safety and key efficacy measurements, including changes in muscle αDG glycosylation levels and changes in functional measures, including a 10-meter walk and North Star for Dysferlinopathy.
  • Price Action: BBIO increased 4.53% at $66.7 in the market trading hours on last check Friday.
 

Related Articles (BBIO)

View Comments and Join the Discussion!

Posted-In: LGMD2iBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com